BioSpace News Archive

Kronos Bio, Inc. announced that its two novel investigational spleen tyrosine kinase inhibitors, entospletinib and lanraplenib, will be featured in poster presentations at the European Hematology Association 2022 Congress, being held June 9-12 in Vienna.

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that an abstract providing safety and efficacy data from the ongoing CTX130™ clinical trial for patients with T-cell lymphoma has been accepted for oral presentation at the Annual European Hematology Association (EHA) 2022 Hybrid Congress.

NeoTX announced the acquisition of InterX. InterX, is a drug discovery company utilizing advanced proprietary tools of biomolecular computation for the discovery and design of novel therapeutic molecules based on Nobel Prize Laureate Prof Michael Levitt’s discoveries.

MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced that new data on pelabresib and tafasitamab, marketed in the U.S. as Monjuvi® and in Europe as Minjuvi®, will be presented during the 2022 American Society of Clinical Oncology Annual Meeting (ASCO 2022) in Chicago from June 3 – 7, 2022 and the 2022 European Hematology Association Hybrid Congress (EHA 2022) in Vienna, Austria, from June 9 – 12, 2022.

Cancer is the second leading cause of death and cancer care costs $1 trillion annually.

Lunaphore, and Indica Labs, today announced a partnership to co-market an end-to-end solution that combines Lunaphore’s flagship COMET™ spatial biology platform and Indica’s HALO® and HALO AI™ digital pathology image analysis software.

Jerome Canady Research Institute for Advanced and Biological Technological Sciences (JCRI-ABTS) and US Medical Innovations, LLC (USMI) announced today that Jerome Canady MD, Chief Science Officer at JCRI-ABTS and a Surgical Oncologist at Holy Cross Hospitals Silver Spring/Germantown, MD will present the results of a Two-year follow up.

In preclinical animal studies, NVG-291 has demonstrated the potential to promote repair mechanisms in the nervous system, including axonal regeneration, remyelination, and plasticity.

Akston Biosciences Corporation, a developer of new classes of biologic therapeutics, announced today it dosed the first set of volunteers in an open-label study of AKS-452, its protein subunit COVID-19 vaccine, as a booster.

Chimeric antigen receptor (CAR) T-cell therapy is a novel class of immunotherapy which involves genetically engineered T-cells to allow recognizing and targeting the tumor cell.